Last reviewed · How we verify
oral cromolyn sodium
Oral cromolyn sodium, developed by the University of Tennessee, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term use. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | oral cromolyn sodium |
|---|---|
| Also known as | Gastrocrom |
| Sponsor | University of Tennessee |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS (PHASE2)
- The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life
- Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis (PHASE4)
- Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment (PHASE3)
- Masitinib for the Treatment of Severe Mast Cell Activation Syndrome (PHASE2)
- Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers (PHASE1)
- Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI) (PHASE2)
- Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oral cromolyn sodium CI brief — competitive landscape report
- oral cromolyn sodium updates RSS · CI watch RSS
- University of Tennessee portfolio CI